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Pisa, Italy
The natural history of the immune thrombocytopenia (ITP) is interesting and intriguing 
because it traces different steps underlying autoimmune diseases. The review points out 
the main steps that have accompanied the stages of its history and the consequential 
changes related to its terminology. ITP is an autoimmune disease resulting from platelet 
antibody-mediated destruction and impaired megakaryocyte and platelet production. 
However, research advances highlight that a complex dysregulation of the immune 
system is involved in the pathogenesis of this condition. The review examines the role 
of the multiple immune components involved in the autoimmunity process, focusing on 
the more recent mechanisms, which could be new promising therapeutic targets for ITP 
patients.
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iNTRODUCTiON
Immune thrombocytopenia (ITP) is a blood disorder characterized by a low platelet count and 
mucocutaneous bleeding. The severity of bleeding generally correlates with the severity of throm-
bocytopenia. Its estimated incidence is 100 cases out of a million people per year; about half of these 
cases occurs in previously healthy children, where it represents the most frequent blood disorder. The 
etiology of ITP is still unknown, and the diagnosis continued to be one of exclusion: the appropriate 
methodological approach will be described in the second part of the review. Since the beginning of the 
century, its long history brought new insights about the pathogenesis of the disorder, leading to better 
refining of both terminology and clinical states. Although the platelet destruction by autoantibodies 
is considered the main pathogenetic mechanism, a complex dysregulation of the immune system is 
observed in ITP patients. Autoantibodies also may fix complement to platelets, T-cell and cytokine 
profiles are shifted to type 1 immune response, and the monocytic phagocytic system appears to 
be excessively activated, resulting in a pathogenic loop (1). In addition, several negative immune 
regulators such as T and B regulatory cells (Tregs, Bregs) and tolerogenic dendritic cells (DCs) are 
dysfunctional, enable to efficiently suppress the pathogenic process (1). The recently discovered T 
follicular helper cells (TFHs) are reported to be involved in B cell recruitment and differentiation in 
the spleen of ITP patients (2). Therefore, the autoimmune attack on platelets (and megakaryocytes) 
is amplified by multiple mechanisms. Together with the antibody suppression of megakaryopoiesis 
and thrombopoiesis, also other mechanisms such as abnormal apoptosis and thrombopoietin (TPO) 
dysregulation are described (3–7). Further, genetic factors are thought to play a role in susceptibility 
to developing ITP (8, 9). The knowledge of the multiple immune defects has opened new therapeutic 
opportunities that we will discuss in the next second part of the review.
TABLe 1 | The historical view of iTP.
Year Author Main discovery
1915 Frank (33) Toxic factor produced by the spleen
1916 Kaznelson (34) Increased platelet destruction in the 
spleen
1938 Troland and Lee (35) “Thrombocytopen” factor in the 
spleen
1946 Dameshek and Miller (11) Abnormality of the spleen
1951 Harrington et al. (36) Plasmatic factor
1951 Evans et al. (37) Antiplatelet autoantibodies
1965 Shulman et al. (12) Isotype of autoantibodies
1975 Dixon et al. (13)
1978 McMillan et al. (23) Anti-megakaryocyte autoantibodies
1982 Van Leeuwen et al. (38) Anti-glycoprotein autoantibodies
1991 Semple et al. (39) T cell abnormalities
1994 Bartley et al. (18) Thrombopoietin
Kuter et al. (19)
Lok et al. (20)
1996 Wright et al. (40) Molecular mimicry
2003 Olsson et al. (31) Cytotoxic T cell involvement
2003 Chang et al. (26) Anti-megakaryocyte autoantibodies
2004 McMillan et al. (27)
2004 Houwezijl et al. (28) Megakaryocytic abnormalities
2005–2016 Involvement of multiple components of the immune system in a 
complex interplay
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THe iNTRiGUiNG HiSTORY OF iTP
The history of ITP is interesting and intriguing because it traces 
the different steps underlying autoimmune diseases. It starts 
with the identification of platelets into the blood, goes round 
the definition of the immuno-pathogenetic mechanisms, and 
ends by opening the window for new therapeutic options in the 
field of autoimmune disorders (Table  1). Many evolving con-
cepts have subtended the pathophysiology of ITP. The historical 
perspective of ITP has been detailed in the outstanding review 
of Stasi and Newland (10), where the readers can found exciting 
suggestions for the comprehension of developing steps of ITP 
pathophysiology, as if it were a model of autoimmune disorder. 
Our review summarizes the essential points that mark the his-
tory of this disease. In 1915, Frank proposed that ITP resulted 
from the suppression of platelet production by megakaryocytes 
(MKs), due to a toxic factor produced by the spleen. The follow-
ing year, based on the evidence that splenectomy normalized 
the platelet count in many patients with ITP, a medical student 
called P. Kaznelson, radically changed Frank’s hypothesis. He 
suggested that thrombocytopenia was due to an increased plate-
let destruction in the spleen, focusing on the critical role of the 
spleen in the pathogenesis of ITP. Furthermore, the mechanism 
of the spleen platelet destruction remained to be clarified, if by 
the direct destruction or by the release of an inhibiting factor. In 
1938, Troland and Lee experienced that the injection of a sub-
stance (thrombocytopen) into the rabbits, extracted from spleen 
of patients with ITP, consistently produced a rapid, although 
transient, fall of the platelet count. Despite of this, other Authors 
affirmed that the disease was due to a fundamental abnormality 
of the spleen, which “exerted an unusual effect upon the produc-
tion of platelets from the megakaryocytes in the marrow” (11). 
In 1951, Harrington–Hollingsworth experiments unequivocally 
settled the debate about the mechanism of the ITP thrombo-
cytopenia, i.e. peripheral platelet destruction versus impaired 
platelet production. They demonstrated that healthy volunteers 
(Harrington included!), who received a blood transfusion from 
patient with ITP, became thrombocytopenic, concluding that 
ITP was characterized by reduced platelet survival due to a 
plasmatic factor. In the same year, Evans et  al. suggested that 
the thrombopoietic factor was an antiplatelet antibody, identi-
fied as immunoglobulin (Ig) of G isotype (12). Its increase was 
subsequently demonstrated in 90% of chronic ITP patients (13). 
In 1982, new investigations about the antibody components 
of ITP, performed by Van Leeuwen et  al., demonstrated that 
ITP patients produced autoantibodies against two platelet 
glycoproteins (GP), GPIIb and GPIIIa. Since that time, several 
laboratories have provided direct evidence for the presence of 
autoantibodies against GPIIb/IIIa and other platelet antigens in 
PTI (14–17). In 1994, the primary regulator of platelet produc-
tion, called thrombopoietin, was purified and cloned (18–20); 
its role in the pathophysiology of ITP, underlying inappropriate 
thrombopoiesis in most patients, has been suggested (21, 22). 
In 1996, Wright et  al. elucidated the cross-reactive nature of 
these autoantibodies, introducing in the ITP pathogenesis, the 
hypothesis of “molecular mimicry,” resulting in loss of tolerance 
and the activation of the autoimmunity mechanisms. Since the 
early 1980s, several studies have supported the hypothesis that 
thrombocytopenia might result not only from antibody platelet 
destruction but also from antibody against megakaryocytes 
(23–25). The role of autoantibodies in patients with ITP has been 
further defined by in  vitro experiments, supporting the view 
that autoantibodies in ITP either suppressed MKs production 
or maturation and platelet release (26, 27). Other investigators 
confirmed the involvement of megakaryocytes, by showing in 
ITP patients, extensive megakaryocytic abnormalities sugges-
tive of a mechanism of “non-classical apoptosis” (28). Already 
since 1991, Semple et al. suggested that not only the antibody 
response but also T cell compartment was involved with multiple 
abnormalities in the pathogenesis of ITP. In particular, they 
showed that the disorder might be the result of an abnormal 
T helper (Th) cell defect, that could direct autoreactive B cells 
to produce autoantibodies. Therefore, ITP was considered a 
disease due to an immune system multi-dysfunction, in which 
not only the T helper cells were involved, but also T regulatory 
cells that might play a role in the persistence of disease through 
the loss of tolerance (29, 30). Olsson et al., in 2003, brilliantly 
discovered that cytotoxic T (Tc) cells in ITP patients, deprived 
of platelet antibodies, could cause thrombocytopenia (31). 
Subsequent studies in 2007, suggested that CD8+ T cells lead 
to impaired platelet production, by suppressing autologous MK 
apoptosis (32). From the year 1951, that marked the beginning of 
the era of the immunologic character of ITP, focusing as central 
theme “the autoantibody-platelet destruction,” ITP pathogenesis 
appears to be multifactorial, resulting as a complex interplay 
involving multiple components of the immune system. The 
considerable advances in immunology over the past two decades 
expanded our knowledge about the immune defects underlying 
the ITP pathogenesis and allowed the development of “targeted 
therapies.”
FiGURe 1 | Old and new definition of the different stages of disease 
(immune thrombocytopenia).
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New TeRMiNOLOGY AND CHANGeS 
OF DeFiNiTiON OF THe DiFFeReNT 
PHASeS OF iTP
Based on the above described story, in 2009, the International 
Working Group (IWG), following the Consensus Conference 
in Vicenza, Italy (the Vicenza Consensus Conference, October 
2007), proposed a new terminology, with the aim to underline the 
autoimmune pathogenesis of ITP [(41); Figure 1]. IWG decided 
to maintain the acronym ITP, recognizing its historical origin, 
but changing the meaning. The acronym ITP means “IMMUNE 
THROMBOCYTOPENIA”: the letter “P” today means “Primary” 
and replaces the outdated “Purpura,” which is considered an inap-
propriate term to describe the disorder, being the symptoms (like 
purpura) absent in most cases. Instead, the term “primary” refers 
to the absence of a recognized cause of the disease. Additionally, 
the IWG clearly distinguished between primary and secondary 
forms, in which thrombocytopenia is due to an underlying disease 
present at diagnosis (42). Unless otherwise specified, ITP refers to 
the primary form of immune thrombocytopenia. Along with the 
change of terminology concerning the disease definition, also the 
definition of its different phases has been changed. Traditionally, 
the definitions “acute ITP” and “chronic ITP” have been used 
to identify respectively a self-limited form of the disease (e.g., 
secondary to viral infection in children) and a lasting for more 
than 6 months form. Currently, as reliable predictive clinical and 
laboratory signs of disease duration have not yet been identified, 
the term “newly diagnosed ITP” is used to define all cases at 
diagnosis (41). In most cases (85%), the disease is self-limited, 
reaching a complete remission in 3–6 months from diagnosis. It 
is typically observed in children, both male and female with the 
same incidence, showing (in 50–60% of the cases) a recent history 
of viral disease. Twenty percent of cases do not achieve spon-
taneous remission or do not reach or maintain remission after 
treatment in the period lasting between 3 and 12 months from 
diagnosis; the new term “persistent ITP” is introduced to define 
these ITP patients. Furthermore, the term “chronic ITP” is used 
for patients with ITP lasting for more than 12 months. The only 
term that is historically maintained is “refractory ITP,” referred to 
the chronic form that is not responsive to the treatment.
PATHOGeNeSiS
Immune thrombocytopenia is historically considered an autoim-
mune disease attributed to platelet destruction due to antibodies 
secreted by autoreactive B cells. Moreover, continued research 
provided evidence that an impaired platelet production is also 
important in the pathogenesis of ITP, leading new insights into 
the comprehension of the complex immunopathogenic mecha-
nisms underlying this disease (43, 44). The triggering event of 
ITP is unknown, and it is still unclear whether the immune 
defects associated with ITP play causative roles in the disease or 
are secondary epiphenomena (evoked by the structural platelet 
glycoprotein modifications) brought on by the inflammation 
associated with the disorder (44). Furthermore, a complex array 
of the immune mechanisms involved in the ITP autoimmunity 
has been delineated in the recent years.
effects of Autoantibodies on Platelets 
and Megakaryocytes
Classically, the primary event of ITP is the arising of autoanti-
bodies opsonizing platelets that leads to a markedly enhanced 
Fc-receptor (Fc-R)-mediated clearance of platelets by the 
monocytic phagocytic system (macrophages and dendritic cells) 
residing in the spleen (and liver) (43). Both platelet destruction 
and impaired platelet production are primarily mediated by IgG 
autoantibodies, although IgM and IgA may be involved (45, 46), 
mainly directed against platelet membrane glycoprotein com-
plexes, such as GPIIb/IIIa and GPIb/IX (2, 47); other GP (Ia–IIa, 
IV, and V) have also been identified (46). Furthermore, it has 
been demonstrated that the two most frequent platelet membrane 
glycoprotein targets, GPIIb heterodimer and GPIb/IX complex, 
were also expressed on megakaryocytes during the early stages of 
differentiation (48). Moreover, autoantibodies were also found to 
bind MKs (23). In the late 1960s, animal models provided the first 
demonstration that autoantibodies might not only cause periph-
eral destruction of mature platelets but also directly affect MKs. 
Subsequently, in a study of pediatric patients suffering from ITP, 
a significant suppression of in vitro MK production was observed, 
when the plasma samples contained anti-GPIb/IX antibodies 
alone or in combination with anti-GPIIb/IIIa antibodies (26). By 
using MK cultures derived from human CD34+ cell, it has been 
recently demonstrated that antiplatelet antibodies inhibited pro-
platelet formation by MK and, therefore, their ability to release 
platelets (49). Additionally the discover of an autoantibody-
antigen target, the Mpl TPO receptor (the cellular homolog of 
the myeloproliferative leukemia virus oncogene), allowed to 
demonstrate, by using plasma derived from thrombocytopenic 
ITP patients in MK colony-forming assays, the suppression of 
MK proliferation by anti-Mpl autoantibodies (50).
The Role of Complement
There are clear indications that complement activation is involved 
in the disappearance of platelets from the circulation of patients 
with ITP (51), although its role and that one of complement 
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receptors in the pathogenesis of ITP are poorly understood 
(52). The autoantibodies, specifically bound to platelet antigens, 
can fix complement (C3) on platelet and megakaryocyte (MK) 
membranes, triggering cell destruction through complement 
system, either by enhancing clearance or direct cell destruction. 
Subsequent studies have described the intrinsic ability of platelets 
to activate both classical (53, 54) and alternative (52, 55) pathways 
of complement.
Other Mechanisms of impaired 
Thrombopoiesis
Platelet kinetic studies suggested that both impaired platelet 
production/destruction might be determined not only by 
autoantibody suppression of both megakaryopoiesis and 
thrombopoiesis, but also by other mechanisms such as abnormal 
apoptosis and TPO dysregulation (3, 4). Although an increased 
number of mature megakaryocytes compared to normal con-
trols are observed in ITP patients, the maturation program 
of these cells appears to be impaired. The histopathology and 
ultrastructural abnormalities of bone marrow of the majority 
of patients are consistent with an apoptosis-like programed 
cell death (28). Elevated apoptosis markers and an increased 
proportion of megakaryocytes with activated caspase-3 have 
been observed in bone marrow biopsies of ITP patients (28). 
TPO is the primary regulator of megakaryocytopoiesis and 
thrombopoiesis, supporting cell survival, cell cycling, and 
modulating apopotosis and cell cycle regulators (46). Patients 
with ITP, considering their often extremely low platelet count, 
characteristically exhibited lower than expected levels of 
endogenous TPO (eTPO) (56–58). It has also been observed 
that, although in the presence of similar platelet counts, eTPO 
levels in ITP patients were markedly lower than those observed 
in patients with aplastic anemia (5, 48, 59). The reason of this 
unexpected observation could be explained because of binding 
to Mpl on the increased MK mass with subsequent internaliza-
tion and degradation or secondary to TPO bounds to platelets 
targeted for destruction (46). Furthermore, the observation 
of reduced TPO levels in the presence of low platelet count 
suggested impaired platelet production and failure to compen-
sate for the thrombocytopenia (48). However, other studies 
comparing eTPO and platelets counts in ITP patients reported 
conflicting results (5, 6). Although the prevailing model of 
steady-state TPO regulation is based on the circulating TPO 
concentration inversely proportional “to Mpl mass,” a novel 
physiological feedback mechanism has been documented. 
Grozovsky et  al., in 2015, demonstrated that the circulatory 
lifespan of platelets was determined by sialic acid loss that 
triggers platelet removal by the hepatic Ashwell–Morell recep-
tor (AMR). The AMR is a transmembrane heteroligomeric 
glycoprotein complex composed of ASGPR1 (CLEC4H1, 
HL-1) and ASGPR2 (CLEC4H2, HL-2) subunits, which are 
highly conserved among mammalian species (7, 60). The 
AMR-mediated removal of desialylated aged platelets regulates 
TPO synthesis in the liver by recruiting janus kinase2 (JAK2) 
and transcrption3 (STAT3) phosphorylation (7). These data 
contribute to explain “the plasma TPO-level discrepancies” 
observed in human pathologic conditions, characterized by 
thrombocytopenia and liver disease, abovementioned. In fact, 
the antibody-mediated clearance of sialylated platelets would 
avoid the AMR platelet removal and, therefore, reduce TPO 
expression (7). These studies opened an interesting window 
of opportunity, indicating TPO receptor agonists (TPO-RA) 
as an alternative treatment option for children with chronic 
ITP. Clinical trials in children are ongoing and data are emerg-
ing on safety and efficacy of these agents (61). Although the 
autoantibodies-mediating accelerated platelet clearance from 
the circulation continues to be the central theme in the current 
understanding of ITP, its pathogenesis appears to be multi-
factorial, resulting as a complex interplay involving multiple 
components of the immune system (Figures 2 and 3).
The Role of Antigen-Presenting Cells
Following the exposition to the cell surface of “cryptic” antigens, 
the appearance of a wide spectrum of new peptides can therefore 
induce an “acquired cell recognition of new self-determinants” 
by the antigen-presenting cells (APC), playing a crucial role not 
only in the arising but also mainly in the progression of the ITP 
(62). These cells in normal conditions play the primary function 
of recognizing, binding to and internalizing protein antigens 
for endosomal proteolytic degradation. After these peptides 
complexed with MHC molecules are presented to T cells in 
conjunction with signaling costimulatory events (i.e., CD28/B7 
and CD80/86 interactions between APC and T cell), and in the 
presence of appropriate cytokines, the T cell become properly 
activated (44). The local microenvironment and extrinsic stimuli 
can influence APC phenotype and function; in certain condi-
tions, such as inflammation, APC abnormalities, in number and 
function, lead to abnormal processing or presentation of self 
antigens or inappropriate T cell activation. Dendritic cells, even 
referred as professional APC, are the most specialized among all 
leukocytes in the presentation of antigen. Peripheral blood DCs 
are classified in two broad groups according to their lineage, 
myeloid DCs (mDCs), often referred as conventional DCs, and 
plasmacytoid DCs (pDCs) (63). The mDC subset plays specific 
functions in the initiation of adaptive immune response, being 
critical for the activation of effector T cells and differentiation of 
naive CD4+ T cells into Th1 cells. The pDCs produce high levels of 
type I interferon (IFN-α/β/ω), reflecting their important function 
in antiviral immune responses (1, 63–65). The type I IFN is a 
pleiotropic cytokine not only with antiviral properties but also 
with capability to regulate pDC survival, mDC differentiation, 
mDC-mediated cytotoxic T cell responses, cross presentation, 
upregulation of costimulatory MHC molecules, and activation of 
natural killer (NK) and B cells (63, 66–69). Plasmacytoid DCs also 
display pro-inflammatory and immunosuppressive tolerogenic 
properties (70). Recently, low number of circulating pDCs has 
been shown in untreated patients with ITP (65). These authors 
explained this result as an abnormality of their distribution and 
suggested that pDCs could be mobilized into peripheral inflamed 
tissues, particularly to the spleen. Together with the pDC number 
alteration, also the dysfunction of DCs has been demonstrated 
to contribute to the development of ITP (71). In experiments 
performed by pulsing DCs from ITP patients and healthy donors, 
FiGURe 2 | Picture of interplay of contributing factors in iTP. The triggering event for ITP is substantially unknown. Genetic factors may play an important role 
in the development of the disease, being associated with increased susceptibility to infections or predisposition to autoimmune diseases. The generalized immune 
dysregulation, with an imbalance between the immunoregulatory elements (cells, receptors, cytokines, and other signaling molecules), regulatory and effector 
T cells, drives pathogenic T and B cell effector responses against platelets and megakaryocytes. 
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with autologous/allogeneic fresh and aged platelets, Catani et al. 
(71) showed that the DCs from patients stimulated T-cell prolif-
eration in a greater degree than those one from healthy donors. 
They concluded that this might be due to an increased expression 
of the costimulatory antigen CD86 on the surface of DC patients 
(71). The importance of the ITP dysregulation of the APC-T cell 
cross talk has been reported by Zhong et al. (72).
The Role of Cytotoxic Cells
Cytotoxic T lymphocytes (CTLs) are cells able to kill neoplastic 
or infected cells with bacteria or viruses by programing these 
cells to undergo apoptosis (73). In ITP patients, with no iden-
tifiable anti-platelets autoantibodies, CTLs have been shown to 
increase both platelet and MK lysis, suggesting the role of these 
cells in mediating thrombocytopenia (31, 32, 74–76). Apoptosis 
and perforin/granzyme-mediated cytotoxicity constitute the 
main pathway used by CTLs to destruct autologous platelets 
(75). A variety of T cell and cytokine abnormalities have been 
observed in patients with ITP, suggesting that T cell-mediated 
peripheral platelet destruction and MK destruction/inhibition 
could be involved in the pathogenetic mechanism of throm-
bocytopenia (26, 27, 31, 44, 77–79). Interleukin-27 (IL-27), 
a member of IL-12 family, is a cytokine with multiple immu-
nomodulatory functions, showing both pro-inflammatory 
and anti-inflammatory effects (80). Liu et  al. demonstrated 
low plasma and mRNA expression levels of IL27 in active ITP 
patients, suggesting that this cytokine might be involved in 
the pathogenesis of ITP (81). Recent data suggested that IL-27 
could inhibit platelet destruction by negatively regulating CTL 
cytotoxicity toward autologous platelets in ITP (80); this nega-
tive regulation was obtained by decreasing granzyme B expres-
sion whereas granzyme A and perforin were not affected (80). 
Based on these experiments, it has been suggested that IL-27 
might have a therapeutic role in ITP patients (80). Thus, in addi-
tion to platelet-specific autoantibodies, also CTLs and aberrant 
cytokine profiles can be involved in platelet destruction, playing 
important role in the pathogenesis of ITP (73, 80).
T Follicular Helper Cells
T follicular helper cells are the specialized providers of B cell help; 
they are the key cell type required for the formation of germi-
nal centers (GCs) and the generation of long-lived serological 
memory. TFHs have emerged to play a key role in regulating 
the humoral immune response that occurs with autoimmune 
diseases, infectious diseases, and tumors (82). TFHs are charac-
terized by low expression levels of cytokines, IFN-γ, IL-4, and 
IL-17, characteristic of Th1, Th2, and Th17 cells respectively 
and by the expression of effector molecules that are critical for 
their development and function, including chemokine receptor 
5 (CXCR5), inducible costimulator (ICOS), programed death-1 
(PD-1), surface receptors of IL-21, IL-6, CD40, and transcription 
factors Bcl-6 and c-Maf (2, 83). It has been demonstrated that 
human splenic TFHs are the main producers of interleukin IL-21 
(2), a cytokine playing a critical role in T cell and B cell homeo-
stasis. In B cells, IL-21 signaling is involved in germinal center 
formation, Ig-secreting B cells, and antibody response (83, 84), 
while in CD4 T cells, it promotes the development of Th17 and 
TFHs themselves (83–85).
FiGURe 3 | Pathogenic loop in immune thrombocytopenia. Schematic picture of a continuous pathogenic loop carried out by APC, autoreactive CD4+ T cells, 
and autoantibody-producing B cells that maintains antiplatelet antibody production in ITP patients. A defect in the immune regulatory compartment (DCs, Tregs, 
Bregs) did not suppress the interaction between APC and autoreactive CD4+ T cells, resulting in prevention from a trigger of the pathogenic loop. APC, antigen 
presenting cell; GP, glycoprotein.
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In ITP patients, splenic TFH frequency is higher than healthy 
donors and correlates with germinal center and plasma cell 
percentages that are also increased (2). Although the role of the 
inflammatory environment in the increase in TFH frequency 
could not be completely excluded, Audia et al. (2) strongly sug-
gested that the expansion of TFHs could be involved in B-cell 
recruitment and differentiation in the spleen of ITP patients, 
through IL-21 secretion and by the interaction of CD154 with 
CD40, contributing to the development of plasma cells produc-
ing antiplatelet autoantibodies. Therefore, TFHs and associated 
molecules, such as IL-21 and CD40, could be new promising 
therapeutic targets for ITP patients.
The Loss of Tolerance
The Th1/Th2 Balance
Immune homeostasis is maintained via a balance of two types of 
responses, defined by cytokine secretion profiles. The responses 
of type 1, characterized primarily by IL2, IFNγ, TNFα, and 
TNFβ1 production, are involved in response to intracellular 
pathogens and generally promote pro-inflammatory, cell-
mediated, complement fixing phenotypes. On the other hand, 
type 2 reactions, characterized by IL4, IL5, IL6, IL10, and IL13 
cytokine production, function in the fight against extracellular 
pathogens, and typically elicit an immediate-type hypersensitiv-
ity response (43). The polarization of the immune system toward 
either type 1 or type 2 immunity is dependent on the level of 
the cytokines. In ITP, type 1/type 2 ratio is unbalanced, shifted 
toward a type 1 phenotype, favoring autoreactive B cell develop-
ment (a Th2 phenotype being observed in patients during remis-
sion or during intravenous immunoglobulin treatment) (1, 43, 
86, 87). This has been attributed to the reduction of peripheral 
Th2 cells, of Tc2 cells and of CD25brightFoxp3+ Tregs either in 
number or in function (30, 43, 87–90). Zhong et al. (72) showed 
that the CD16+ monocyte subset from the peripheral blood of 
chronic ITP promoted the expansion of the Th1 subset via IL12 
secretion, while inhibited the proliferation of Th17 cells and the 
induction of Tregs. The Th1/Th2 balance in ITP is showed in 
Figure 4.
FiGURe 4 | Schematic cell imbalance in iTP. Dysregulation of T cell 
activity and cytokine abnormalities are critical for ITP development. The 
unbalanced type 1/type 2 ratio leads to autoreactive B cell differentiation. 
Reduced number and/or impaired function of Tregs, Bregs, and tolerogenic 
DCs may contribute to enhance the immune activation. Bregs, B regulatory 
cells; pDCs, plasmacytoid dendritic cells; Tregs, T regulatory cells; 
Th, T helper cells; Tc, T cytotoxic cells.
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Treg and Th17 Compartments
Tregs are a subpopulation of T cells specialized in immune sup-
pression and contribute to the maintenance of peripheral immune 
tolerance; their defects are thought to play a role in the patho-
genesis of various autoimmune diseases (91). In the last decade, 
data from numerous studies have demonstrated a dysregulation 
of Treg cell population in ITP (29, 30, 91–102). Treg deficiency 
was reported in both adults and children with ITP (91): the lowest 
Treg frequency was detected in patients with acute phase of the 
disease and/or with low platelet count, while Tregs increase was 
observed in remission phase. Interestingly, a failure of the cross 
communication between DCs and Tregs in patients with ITP has 
been reported (103). These authors showed that the decreased 
expression and/or activity of the immunomodulatory enzyme 
indoelamine 2,3-dioxygenase 1 (IDO1) by DCs, contributed to 
the reduced conversion from T cells into Tregs, suggesting the 
importance of the cross talk between DCs and the adaptative 
immune system in the pathophysiology of immune thrombo-
cytopenia (103). T cell-related pro-inflammatory cytokines may 
play a pivotal role in immune dysregulation during active ITP. In 
the past years, increased levels of macrophage colony-stimulating 
factor (M-CSF) (causing a stimulus for to the platelet antigen 
presentation by macrophages to T cells), reduced levels of trans-
forming growth factor (TGF)-β production have been described 
in children with chronic ITP (104). IL10 is a cytokine with 
anti-inflammatory properties; initially described as a product 
of Th2 cells able to inhibit cytokine synthesis of Th1 cells (105), 
IL-10 is now known to be produced by many different types of 
cells, including Tregs (106). Based on data showing that IL10 
producing Tregs contributed to the effective control of several 
autoimmune diseases (107), a recent study investigated the role of 
this cytokine in newly diagnosed ITP patients (106). The Authors 
identified a numerical and functional defect of Tregs associated 
with an excessive activation T effector cells, suggesting that the 
assessed insufficient secretion of IL-10 could compromise the 
inhibitory capability of Tregs against T effectors cells and play 
a major role in the exuberant CD4+ T cell immune response of 
ITP (106). More attention has been deserved to IL17, a cytokine 
produced by Th17 cells, a newly defined CD4+ Th subset; Th17 
cells modulate the pro-inflammatory response by producing, as 
well as IL17, also IL6, IL21, tumor necrosis factor (TNF), and 
other mediators (108–110). Thus, while Treg cells play a funda-
mental role in the maintenance of immune tolerance to prevent 
autoimmune disease, Th17 cells play the opposite role. Indeed, 
it has been demonstrated that Th17 cells are more potent than 
Th1 cells in inducing autoimmune disorders (111–113). Several 
reports support a role for IL17 in the pathogenesis of ITP. Rocha 
et al. (110) suggested that increased levels of IL17 and of Th17-
related cytokines found in adult patients with chronic ITP might 
contribute to the disease pathogenesis. The Treg/Th17 imbalance 
has been found associated with disease activity among adult ITP 
patients, implying an association between Th17 cell elevation 
and the development of ITP and suggesting a prognostic role of 
this cytokine (114). Wang et al. (115) found that IL17 levels were 
elevated in pediatric patients with chronic ITP and positively cor-
related with INFγ expression, suggesting that both Th17 and Th1 
might be simultaneously involved in the dysregulation of cellular 
immunity observed in pediatric patients. However, other groups 
did not report significant differences either in the serum levels or 
in the expression of IL17 on peripheral blood mononuclear cells 
between ITP patients and normal controls (116, 117), arguing 
that IL17 might not play an important role in the pathogenesis 
of adult patients with chronic ITP. These conflicting results con-
cerning the IL17 role underline the variability in the clinical 
phenotype and evolution of the disease duration among the ITP 
population. The IL23/IL17 axis is critical for the development of 
inflammatory diseases. IL23, which is mainly secreted by APCs, 
is the pivotal mediator responsible for the differentiation of naive 
CD4+ T cells into Th17 cells; the importance of the IL23 cytokine 
and of its receptor in both Th17 maturation and function has been 
demonstrated (113, 118, 119). Several studies reported that the 
IL23/Th17 pathway was strongly involved in the pathogenesis of 
many autoimmune diseases, such as rheumatoid arthritis (120), 
multiple sclerosis (121), primary biliary cirrhosis (122), and 
inflammatory bowel disease (123). However, less is known with 
regard to the levels of expression and synthesis of these two 
cytokines in patients with ITP. The role of IL23/Th17 pathway 
in adult ITP patients has been recently investigated (113). These 
Authors, found higher levels of IL17 and IL23 in patients with ITP 
than in controls and a decrease of both cytokines after effective 
treatment, suggesting that IL23 was engaged in the development 
of ITP through enhancement of the Th17 response.
The Role of Bregs
Interestingly, Bregs are a distinct B cell population with potent 
immunoregulatory properties; among them, the most well subset 
characterized is the IL10-producing subset (B10 cells) (1, 124, 
125), which plays an important role in autoimmune diseases 
(1, 87, 126, 127). Recent findings showed that IL10 produced by 
B10 cells is required in combination with different costimulatory 
molecules for the differentiation and maintenance of Tregs and 
for inhibition of Th17 cells (87, 128, 129). Recently, it has been 
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demonstrated that a dysregulation of Breg compartment was 
an additional defect in the immune network in ITP patients 
(1, 87). Hua et al. (87) demonstrated that the number of B10 cells 
positively correlated with both Treg count and Treg/Th17 ratio, 
suggesting that the ability of these cells to regulate functional 
T cell subsets might be impaired in ITP patients.
Genetic Susceptibility
Only a small number of individuals develop ITP after exposure 
to infectious agents. Such variability could be explained by dif-
ferences in genetic factors associated with the host defenses to 
pathogens, such as genes encoding inflammatory cytokines (9). 
In the recent past, genomic studies have allowed the knowledge 
of genetic factors influencing the development of ITP chronic 
pattern. Abnormal polymorphisms have been identified within 
the genes for several inflammatory cytokines. Satoh et  al. (8) 
identified polymorphisms at TNFβ (+252 GG) gene. As TNFβ 
(+252) influences the capacity of T and B cells to produce TNFβ, 
by checking the autoreactive T- and B-cell responses to platelet 
membrane antigens, the Authors suggested that these polymor-
phisms might play a role in an individual’s susceptibility to ITP, 
by promoting the specific autoantibody response. Interestingly, 
a recent study demonstrated that the heterozygous variant (AG) 
genotype of TNFβ was associated with persistent ITP (130). 
Reports about TNF-α-308 gene polymorphisms are conflicting 
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and IL10 (−627) polymorphisms have also been associated with 
the pathogenesis of ITP and believed to contribute to the suscep-
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onstrated that stress-related pathways might contribute to the 
pathogenesis of ITP. In particular, over expression of vanin-1 
(VNN-1), an oxidative stress sensor, has been demonstrated to 
be strongly associated with progression to chronic disease in both 
pediatric and adult patients (9, 139–141).
CONCLUSiON
Since the beginning of the century, new insights have been pro-
vided about the pathogenesis of ITP. Consequently, the nomen-
clature concerning both its definition and evolutionary steps are 
modified. Although the accelerated platelet destruction by platelet 
autoantibodies is considered the hallmark of ITP pathogenesis, 
research advances highlight the complex immune mechanism 
underlying the disease. The continuous fine understanding of 
the contribution of each immune defect (e.g., the checkpoint 
tolerance defect variously involved in ITP patients) could explain 
the clinical diversity and the different tendency to perpetuate 
the disease observed in the ITP population and similarly open 
new windows of opportunities for targeted therapy and “tailored 
treatment.”
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